NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS NASDAQ) stock market data APIs
$37.0593
-0.85(-2.3%)
as of November 7, 2025
Try our APIs with
free plan!
NewAmsterdam Pharma Company N.V. Ordinary Shares Financial Data Overview
Price chart is built with
Anychart
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Prev. Close
37.0593
Open
36.2081
High
37.8945
Low
35.7298
52 wk Range
14.06-41.47
Market Cap
4 168 M
Shares Outstanding
113 M
Revenue
35 243 K
EPS
-0.15
Beta
0.058
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with NewAmsterdam Pharma Company N.V. Ordinary Shares (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NewAmsterdam Pharma Company N.V. Ordinary Shares data using free add-ons & libraries
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental Data
NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental data includes:
- Net Revenue: 35 243 K
- EBITDA: -202 720 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.44
Get NewAmsterdam Pharma Company N.V. Ordinary Shares End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NewAmsterdam Pharma Company N.V. Ordinary Shares News
New
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceut...
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.18 per share a year ago....
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NewAmsterdam Pharma N.V. – Marketing Authorization Applications for obicetrapib and FDC of obicetrapib plus ezetimibe accepted for review by European Medicines Agency – – BROOKLYN and BROADWAY...
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $5.08 per share versus the Zacks Consensus Estimate of a loss of $1.98. This compares to a loss of $4.92 per share a year ago. These figures are adjus...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
